Skip to content

For Canadian Residents Only

Sanofi

Sarclisa (isatuximab)

English Français

Welcome to sarclisa.ca

This site is for people who are being treated with SARCLISA® for multiple myeloma.

SARCLISA® is used to treat multiple myeloma in patients who have received treatments for multiple myeloma before.1

SARCLISA® is used with two other drug combinations:1

  • pomalidomide and dexamethasone; or
  • carfilzomib and dexamethasone

Your healthcare team, as well as the REACH™ Patient Support Program team, will be available to answer any questions you may have.

A close-up image of part of the SARCLISA® logo

Information about SARCLISA®

Learn about SARCLISA® and how it is taken.

What is SARCLISA®? How is SARCLISA® taken?
An image of the front cover of the SARCLISA® Patient Brochure.

Patient Resources

Download helpful documents and find links to other resources.

Learn More
The REACH Program logo

Patient Support Program

The REACH™ Patient Support Program is here for you. Find out how the REACH™ Patient Support Program can help support you during your SARCLISA® treatment.

Learn More?

Reference

  1. PrSARCLISA® Product Monograph. Sanofi Canada. January 12, 2024.

Please Read and Accept the Terms of Use

To enter the site, please confirm you have read and agreed to the terms and conditions below.

Terms of Use

Sanofi operates in Canada through affiliated companies including sanofi-aventis Canada Inc., Sanofi Pasteur Limited and Sanofi Consumer Health Inc. (collectively referred to as “Sanofi Canada”). Sanofi Canada maintains this Website (the “Website”) for your personal information, education and communication. Please feel free to browse the Website.

Through your access and use of the Website, you accept, without limitation or qualification, the terms and conditions (“Terms & Conditions”) set forth at https://www.sanofi.ca/en/terms-conditions and our Privacy Policy, found at https://www.sanofi.ca/en/privacy-policies, incorporated herein by reference. If you do not agree to these Terms & Conditions or the Privacy Policy, you must not access or use the Website.

Please read and accept the Terms of Use before entering the website.